<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NITHIODOTE- sodium nitrite and sodium thiosulfate 
			 </strong><br>Hope Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use the NITHIODOTE safely and effectively. See full prescribing information for NITHIODOTE.<br><br> NITHIODOTE (sodium nitrite injection USP and sodium thiosulfate injection USP for intravenous infusion).<br> Initial U.S. Approval: 1992 </div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: LIFE-THREATENING <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span> AND METHEMOGLOBIN FORMATION </h1>
<h1 class="Warning">
<span class="Italics">See full prescribing information for complete boxed warning</span>. 								</h1>
<p class="Highlighta"><span class="Bold">Sodium nitrite can cause serious adverse reactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from:</span> </p>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Methemoglobin formation (<a href="#S5.2">5.2</a>)</span></li>
</ul>
<p class="Highlighta"><span class="Bold">Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.</span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: LIFE-THREATENING <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span> AND METHEMOGLOBIN FORMATION </h1>
<h1 class="Warning">
<span class="Italics">See full prescribing information for complete boxed warning</span>. 								</h1>
<p class="Highlighta"><span class="Bold">Sodium nitrite can cause serious adverse reactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from:</span> </p>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Methemoglobin formation (<a href="#S5.2">5.2</a>)</span></li>
</ul>
<p class="Highlighta"><span class="Bold">Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Sodium nitrite and sodium thiosulfate are indicated for sequential use for treatment of acute cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> that is judged to be life-threatening. (<a href="#S1">1</a>) </p>
<ul class="Disc"><li>Use with caution if the diagnosis of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is uncertain. (<a href="#S1">1</a>)</li></ul>
</div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table width="52%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="87%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Age</th>
<th class="Rrule" align="left">Intravenous Dose of Sodium Nitrite and Sodium Thiosulfate</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Adults</span></td>
<td class="Rrule" align="left"><dl>
<dt class="Bold">1.)</dt>
<dd>
<span class="Bold">Sodium Nitrite </span>-10 mL of sodium nitrite at the rate of 2.5 to 5 mL/minute</dd>
<dt class="Bold">2.)</dt>
<dd>
<span class="Bold">Sodium Thiosulfate </span>- 50 mL of sodium thiosulfate immediately following administration of sodium nitrite.</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Children</span></td>
<td class="Rrule" align="left"><dl>
<dt class="Bold">1.)</dt>
<dd>
<span class="Bold">Sodium Nitrite - </span>0.2 mL/kg (6 mg/kg or 6-8 mL/m<span class="Sup">2</span> BSA) of sodium nitrite at the rate of 2.5 to 5 mL/minute not to exceed 10 mL </dd>
<dt class="Bold">2.)</dt>
<dd>
<span class="Bold">Sodium Thiosulfate - </span>1 mL/kg of body weight (250 mg/kg or approximately 30-40 mL/m<span class="Sup">2</span> of BSA) not to exceed 50 mL total dose immediately following administration of sodium nitrite. </dd>
</dl></td>
</tr>
</tbody>
</table>
<p class="Highlighta"><span class="Italics">Redosing</span>:  If signs of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> reappear, repeat treatment using one-half the original dose of both sodium nitrite and sodium thiosulfate.  </p>
<p class="Highlighta"><span class="Italics">Monitoring</span>:  Blood pressure must be monitored during treatment. (<a href="#S2.2">2.2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>NITHIODOTE consists of:<ul class="Disc">
<li>one vial of sodium nitrite injection, USP 300 mg/10 mL (30 mg/mL) and</li>
<li>one vial of sodium thiosulfate injection, USP 12.5 grams/50 mL (250 mg/mL). (<a href="#S3">3</a>)</li>
</ul>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>None. (<a href="#S4">4</a>)  </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span>: Sodium nitrite reacts with hemoglobin to form methemoglobin and should be used with caution in patients known to have <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Monitor oxyhemoglobin and methemoglobin levels by pulse oximetry or other measurements. Optimally, the sodium nitrite dose should be reduced in proportion to the oxygen carrying capacity. (<a href="#S5.2">5.2</a>)</li>
<li>Smoke inhalation: <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">Carbon monoxide</span> contained in smoke can result in the formation of <span class="product-label-link" type="condition" conceptid="4269049" conceptname="Carboxyhemoglobin">carboxyhemoglobin</span> that can reduce the oxygen carrying capacity of the blood. Sodium nitrite should be used with caution in patients with smoke inhalation injury because of the potential for worsening <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> due to methemoglobin formation. <span class="product-label-link" type="condition" conceptid="4269049" conceptname="Carboxyhemoglobin">Carboxyhemoglobin</span> and oxyhemoglobin levels should be monitored by pulse oximetry or other measurements in patients that present with evidence of smoke inhalation. Optimally, the sodium nitrite dose should be reduced in proportion to the oxygen carrying capacity. (<a href="#S5.4">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are: </p>
<ul class="Disc">
<li>
<span class="Italics">Sodium nitrite</span>:  <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, dysrhythmia,  <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> (<a href="#S6.1">6.1</a>)</li>
<li>
<span class="Italics">Sodium thiosulfate</span>:  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> (<a href="#S6.2">6.2</a>)</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Hope Pharmaceuticals at 1-800-755-9595 or FDA at 1-800-FDA-1088 or<span class="Italics"> www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Sodium nitrite and sodium thiosulfate are substantially excreted by the kidney. The risk of toxic reactions to these drugs may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. (<a href="#S8.6">8.6</a>). </li></ul></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: LIFE THREATENING <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span> AND METHEMOGLOBIN FORMATION</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Indication</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Identifying Patients with Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Use with Other Cyanide Antidotes</a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Administration Recommendation</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Monitoring </a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Incompatibility Information</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2  <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Smoke Inhalation Injury</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Neonates and Infants</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 G6PD Deficiency</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Use with Other Drugs</a></h2>
<h2><a href="#section-5.8" class="toc">5.8  Sulfites</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Sodium Nitrite</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Sodium Thiosulfate</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2	Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> </a></h2>
<h1><a href="#section-9" class="toc">10   OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12. 2        Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and Methemoglobin Formation </a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Monitoring</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: LIFE THREATENING <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span> AND METHEMOGLOBIN FORMATION</span></h1>
<p class="First"><span class="Bold">Sodium nitrite can cause serious adverse reactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in humans, even at doses less than twice the recommended therapeutic dose. Sodium nitrite causes <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and methemoglobin formation, which diminishes oxygen carrying capacity.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and methemoglobin formation can occur concurrently or separately. Because of these risks, sodium nitrite should be used to treat acute life-threatening cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and be used with caution in patients where the diagnosis of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is uncertain</span>. 						</p>
<p><span class="Bold">Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.  </span></p>
<p><span class="Bold">Alternative therapeutic approaches should be considered in patients known to have diminished oxygen or cardiovascular reserve (e.g. smoke inhalation victims, pre-existing <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, cardiac or respiratory compromise), and those at higher risk of developing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> (e.g., congenital methemoglobin reductase deficiency) as they are at greater risk for potentially life-threatening adverse events related to the use of sodium nitrite</span>.<span class="Bold Italics"> [See<a href="#S5.1"> Warnings and Precautions (5.1 </a>and<a href="#S5.2"> 5.2)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Indication</h2>
<p class="First">NITHIODOTE is indicated for the treatment of acute cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> that is judged to be life-threatening. When the diagnosis of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is uncertain, the potentially life-threatening risks associated with NITHIODOTE should be carefully weighed against the potential benefits, especially if the patient is not in extremis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Identifying Patients with Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span></h2>
<p class="First">Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside.</p>
<p>The presence and extent of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. If clinical suspicion of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is high, NITHIODOTE should be administered without delay.</p>
<table width="75%">
<caption><span>Table 1. Common Signs and Symptoms of Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span></span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule" align="left">Symptoms</td>
<td class="Rrule" align="left">Signs</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">Chest Tightness</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
</ul></td>
<td class="Rrule" align="left"><ul class="Disc">
<li>Altered Mental Status<br>(e.g., <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span></li>
<li><span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span></li>
<li><span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">Tachypnea</span>/<span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperpnea</span> (early)</li>
<li><span class="product-label-link" type="condition" conceptid="4314808" conceptname="Slow respiration">Bradypnea</span>/<span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> (late)</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (early)/ <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (late)</li>
<li><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular Collapse</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li>Plasma Lactate Concentration ≥ 8 mmol/L</li>
</ul></td>
</tr>
</tbody>
</table>
<p>In some settings, panic symptoms including <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mimic early cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> signs. The presence of altered mental status (e.g., <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>) and/or <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> is suggestive of true cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> although these signs can occur with other toxic exposures as well.</p>
<p><span class="Bold">The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2.1"></a><p></p>
<p class="First"><span class="Underline">Smoke Inhalation</span></p>
<p>Not all smoke inhalation victims will have cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and may present with <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, and exposure to other toxic substances making a diagnosis of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> particularly difficult. Prior to administration of NITHIODOTE, smoke-inhalation victims should be assessed for the following:</p>
<ul class="Disc">
<li>Exposure to fire or smoke in an enclosed area</li>
<li>Presence of soot around the mouth, nose, or oropharynx</li>
<li>Altered mental status</li>
</ul>
<p>Although <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is highly suggestive of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is a plasma lactate concentration greater than or equal to 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> because <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span> associated with smoke inhalation also contributes to lactic <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidemia</span>). If cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is suspected, treatment should not be delayed to obtain a plasma lactate concentration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Use with Other Cyanide Antidotes</h2>
<p class="First">Caution should be exercised when administering other cyanide antidotes simultaneously with NITHIODOTE, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with NITHIODOTE, these drugs should not be administered concurrently in the same IV line. [see<span class="Italics"><a href="#S2.2"> Dosage and Administration (2.2)</a></span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Administration Recommendation</h2>
<p class="First"><span class="Bold">Comprehensive treatment of acute cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> requires support of vital functions. </span>Administration of sodium nitrite and sodium thiosulfate should be considered adjunctive to appropriate supportive therapies. Airway, ventilatory and circulatory support, and oxygen administration should not be delayed to administer sodium nitrite and sodium thiosulfate.</p>
<p>Sodium nitrite injection and sodium thiosulfate injection are administered by slow intravenous injection. They should be given as early as possible after a diagnosis of acute life-threatening cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> has been established. Sodium nitrite should be administered first, followed immediately by sodium thiosulfate. Blood pressure must be monitored during infusion in both adults and children. The rate of infusion should be decreased if significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is noted.</p>
<table width="70%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="87%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Age</th>
<th class="Rrule" align="left">Intravenous Dose of Sodium Nitrite and Sodium Thiosulfate</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Adults</span></td>
<td class="Rrule" align="left"><dl>
<dt class="Bold">1.)</dt>
<dd>
<span class="Bold">Sodium Nitrite </span>-10 mL of a 3% solution (300 mg) of sodium nitrite at the rate of 2.5 to 5 mL/minute</dd>
<dt class="Bold">2.)</dt>
<dd>
<span class="Bold">Sodium Thiosulfate </span>- 50 mL of a 25% solution (12.5 g) of a sodium thiosulfate solution immediately following administration of sodium nitrite.</dd>
</dl></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Children</span></td>
<td class="Rrule" align="left"><dl>
<dt class="Bold">1.)</dt>
<dd>
<span class="Bold">Sodium Nitrite -</span>0.2 mL/kg of a 3% solution (6 mg/kg or 6-8 mL/m<span class="Sup">2</span> BSA) of sodium nitrite at the rate of 2.5 to 5 mL/minute not to exceed 10 mL (300 mg)       </dd>
<dt class="Bold">2.)</dt>
<dd>
<span class="Bold">Sodium Thiosulfate - </span>1 mL/kg of body weight using a 25% solution (250 mg/kg or approximately 30-40 mL/m<span class="Sup">2</span> of BSA) not to exceed 50 mL (12.5 g) total dose immediately following administration of sodium nitrite. </dd>
</dl></td>
</tr>
</tbody>
</table>
<p>NOTE: If signs of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> reappear, repeat treatment using one-half the original dose of both sodium nitrite and sodium thiosulfate.</p>
<p>In adult and pediatric patients with known <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, it is recommended that the dosage of sodium nitrite should be reduced proportionately to the hemoglobin concentration.<span class="Italics"> [see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span></p>
<p>All parenteral drug products should be inspected<span class="Italics"> visually </span>for particulate matter and discoloration prior to administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Monitoring </h2>
<p class="First">Patients should be monitored for at least 24-48 hours after NITHIODOTE administration for adequacy of oxygenation and perfusion and for recurrent signs and symptoms of cyanide toxicity. When possible, hemoglobin/hematocrit should be obtained when treatment is initiated. Measurements of oxygen saturation using standard pulse oximetry and calculated oxygen saturation values based on measured PO<span class="Sub">2</span> are unreliable in the presence of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.<span class="Italics Underline"> Methemoglobin level</span>: Administrations of sodium nitrite solely to achieve an arbitrary level of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> may be unnecessary and potentially hazardous. The therapeutic effects of sodium nitrite do not appear to be mediated by methemoglobin formation alone<span class="Italics"> [see<a href="#S12"> Clinical Pharmacology (12)</a>] </span>and clinical responses to sodium nitrite administration have been reported in association with methemoglobin levels of less than 10%. Administration of sodium nitrite beyond the initial dose should be guided primarily by clinical response to treatment (i.e., a second dose should be considered only if there is inadequate clinical response to the first dose). It is generally recommended that methemoglobin concentrations be closely monitored and kept below 30%. Serum methemoglobin levels should be monitored during treatment using co-oximetry, and administration of sodium nitrite should generally be discontinued when methemoglobin levels exceed 30%. Intravenous methylene blue and exchange transfusion have been reported in the literature as treatments for life-threatening <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Incompatibility Information</h2>
<p class="First">Chemical incompatibility has been reported between NITHIODOTE and hydroxocobalamin and these drugs should not be administered simultaneously through the same IV line. No chemical incompatibility has been reported between sodium thiosulfate and sodium nitrite, when administered sequentially through the same IV line as described in Dosage and Administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">NITHIODOTE  Injection consists of:</p>
<ul class="Square">
<li>One  vial of sodium nitrite injection, USP 300 mg/10mL (30 mg/mL) and</li>
<li>One vial of sodium thiosulfate injection  USP 12.5 grams/50 mL (250 mg/mL)</li>
</ul>
<p>Administration of one vial of each medication constitutes a single dose. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS </h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </h2>
<p class="First">See<a href="#BOX"> Boxed Warning</a>. Sodium nitrite has been associated with severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at doses less than twice recommended therapeutic doses. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may occur concurrently or separately. Sodium nitrite should be used to treat life-threatening cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. When the diagnosis of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is uncertain and/or the patient is not in extremis, special consideration should be given to administration of sodium nitrite if the patient is known or suspected to have diminished oxygen or cardiovascular reserve (e.g., smoke inhalation victims, pre-existing <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, substantial blood loss, cardiac or respiratory compromise) or to be at higher risk of developing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> (e.g., congenital methemoglobin reductase deficiency).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></h2>
<p class="First">Supportive care alone may be sufficient treatment without administration of antidotes for many cases of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, particularly in conscious patients without signs of severe toxicity. Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.</p>
<p>Methemoglobin levels should be monitored and oxygen administered during treatment with sodium nitrite whenever possible. When sodium nitrite is administered to humans a wide range of methemoglobin concentrations occur. Methemoglobin concentrations as high as 58% have been reported after two 300-mg doses of sodium nitrite administered to an adult. Sodium nitrite should be used with caution in the presence of other drugs that may cause <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> such as procaine and nitroprusside. Sodium nitrite should be used with caution in patients who may be particularly susceptible to injury from vasodilation and its related hemodynamic sequelae. Hemodynamics should be monitored closely during and after administration of sodium nitrite and sodium thiosulfate, and infusion rates should be slowed if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </h2>
<p class="First">Sodium nitrite should be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Patients with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> will form more methemoglobin (as a percentage of total hemoglobin) than persons with normal red blood cell (RBC) volumes. Optimally, these patients should receive a sodium nitrite dose that is reduced in proportion to their oxygen carrying capacity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Smoke Inhalation Injury</h2>
<p class="First">Sodium nitrite should be used with caution in persons with smoke inhalation injury or <span class="product-label-link" type="condition" conceptid="440268" conceptname="Toxic effect of carbon monoxide">carbon monoxide poisoning</span> because of the potential for worsening <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> due to methemoglobin formation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Neonates and Infants</h2>
<p class="First">Neonates and infants may be more susceptible than adults and older pediatric patients to severe <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> when sodium nitrite is administered. Reduced dosing guidelines should be followed in pediatric patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 G6PD Deficiency</h2>
<p class="First">Because patients with G6PD deficiency are at increased risk of a hemolytic crisis with sodium nitrite administration, alternative therapeutic approaches should be considered in these patients. Patients with known or suspected G6PD deficiency should be monitored for an acute drop in hematocrit. Exchange transfusion may be needed for patients with G6PD deficiency who receive sodium nitrite. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Use with Other Drugs</h2>
<p class="First">Sodium nitrite should be used with caution in the presence of concomitant antihypertensive medications, diuretics or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> due to diuretics, or drugs known to increase vascular nitric oxide, such as PDE5 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8  Sulfites</h2>
<p class="First">Sodium thiosulfate drug product may contain trace impurities of sodium sulfite. The presence of a trace amount of sulfites in this product should not deter administration of the drug for treatment of emergency situations, even if the patient is sulfite-sensitive.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">There have been no controlled clinical trials conducted to systematically assess the adverse events profile of sodium nitrite or sodium thiosulfate.</p>
<p>The medical literature has reported the following adverse events in association with sodium nitrite or sodium thiosulfate administration. These adverse events were not reported in the context of controlled trials or with consistent monitoring and reporting methodologies for adverse events. Therefore, frequency of occurrence of these adverse events cannot be assessed. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Sodium Nitrite</h2>
<p class="First"><span class="Italics">Cardiovascular system: </span><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, dysrhythmia</p>
<p><span class="Italics">Hematological: </span><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span></p>
<p><span class="Italics">Central nervous system: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></p>
<p><span class="Italics">Gastrointestinal system: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Italics">Respiratory system: </span><span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Italics">Body as a Whole</span>:  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, injection site <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, generalized <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> </p>
<p>Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in patients without life-threatening cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> but who were treated with injection of sodium nitrite at doses less than twice those recommended for the treatment of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Sodium Thiosulfate</h2>
<p class="First"><span class="Italics">Cardiovascular system: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p><span class="Italics">Central nervous system: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span></p>
<p><span class="Italics">Gastrointestinal system: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Italics">Hematological</span>:  prolonged <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span></p>
<p><span class="Italics">Body as a Whole:  </span>salty taste in mouth, warm sensation over body</p>
<p>In humans, rapid administration of concentrated solutions or solutions not freshly prepared, and administration of large doses of sodium thiosulfate have been associated with a higher incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. However, administration of 0.1 g sodium thiosulfate per pound up to a maximum of 15 g in a 10-15% solution over 10-15 minutes was associated with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in 7 of 26 patients without concomitant cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
<p>In a series of 11 human subjects, a single intravenous infusion of 50 mL of 50% sodium thiosulfate was associated with increases in clotting time 1-3 days after administration. However, no significant changes were observed in other hematological parameters.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">Formal drug interaction studies have not been conducted with NITHIODOTE.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<p class="First">Both sodium nitrite and sodium thiosulfate are Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. NITHIODOTE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Sodium Nitrite</span>:  Sodium nitrite has caused <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> in humans as well as animals. There are no studies in humans that have directly evaluated the potential reproductive toxicity of sodium nitrite. There are two epidemiological studies conducted in Australia that report a statistically significant increase in the risk for congenital malformations, particularly in the CNS, associated with maternal consumption of water containing nitrate levels in excess of 5 ppm. Results from a case-control study in Canada suggested a trend toward an increase in the risk for CNS malformations when maternal consumption of nitrate were ≥ 26 ppm (not statistically significant).</p>
<p>The potential reproductive toxicity of sodium nitrite exposure restricted to the prenatal period has been reported in guinea pigs, mice, and rats. There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in guinea pigs, mice, or rats. However, sodium nitrite treatment of pregnant guinea pigs with 60 or 70 mg/kg/day resulted in abortion of the litters within 1-4 days of treatment. All animals treated subcutaneously with 70 mg/kg, sodium nitrite died within 60 minutes of treatment. Further studies demonstrated that a dose of 60 mg/kg resulted in measurable blood levels of methemoglobin in the dams and their fetuses for up to 6 hours post treatment. Maternal methemoglobin levels were higher than the levels in the offspring at all times measured. Based on a body surface area comparison, a 60 mg/kg dose in the guinea pig that resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was only 1.7 times higher than the highest clinical dose of sodium nitrite that would be used to treat cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> (based on a body surface area comparison).</p>
<p>Studies testing prenatal and postnatal exposure have been reported in mice and rats. Treatment of pregnant rats via drinking water with sodium nitrite at concentrations of either 2000 or 3000 mg/L resulted in a dose-related increased mortality postpartum. This exposure regimen in the rat model would result in dosing of approximately 220 and 300 mg/kg/day (43 and 65 times the highest clinical dose of sodium nitrite that would be used to treat cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, based on a body surface area comparison).</p>
<p>Sodium nitrite produces methemoglobin. Fetal hemoglobin is oxidized to methemoglobin more easily than adult hemoglobin. In addition, the fetus has lower levels of methemoglobin reductase than adults. Collectively, these data suggest that the human fetus would show greater sensitivity to methemoglobin resulting in nitrite-induced prenatal <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> leading to retarded development of certain neurotransmitter systems in the brain and long lasting dysfunction. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline">Sodium Thiosulfate</span>:  There are no reported epidemiological studies of congenital anomalies in infants born to women treated with sodium thiosulfate during pregnancy. In animal studies, there are no teratogenic effects in offspring of hamsters treated during pregnancy with sodium thiosulfate in doses similar to those given intravenously to treat cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> in humans. Other studies suggest that treatment with sodium thiosulfate ameliorates the teratogenic effects of maternal cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> in hamsters. In other studies, sodium thiosulfate was not embryotoxic or teratogenic in mice, rats, hamsters, or rabbits at maternal doses of up to 550, 400, 400 and 580 mg/kg/day, respectively.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Underline">Nonteratogenic Effects:  </span>Behavioral and neurodevelopmental studies in rats suggest persistent effects of prenatal exposure to sodium nitrite that were detectable postnatally. Specifically, animals that were exposed prenatally to sodium nitrite demonstrated impaired discrimination learning behavior (both auditory and visual) and reduced long-term retention of the passive-avoidance response compared to control animals. Additional studies demonstrated a delay in the development of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">AchE</span> and 5-HT positive fiber ingrowth into the hippocampal dentate gyrus and parietal neocortex during the first week of life of prenatal nitrite treated pups. These changes have been attributed to prenatal <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> following nitrite exposure.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2	Labor and Delivery</h2>
<p class="First">Because fetal hemoglobin is more readily oxidized to methemoglobin and lower levels of methemoglobin appear to be fatal to the fetus compared to the adult, sodium nitrite should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">It is not known whether sodium nitrite or sodium thiosulfate is excreted in human milk. Because NITHIODOTE may be administered in life-threatening situations, breast-feeding is not a contraindication to its use. Because many drugs are excreted in human milk, caution should be exercised following NITHIODOTE administration to a nursing woman. There are no data to determine when breastfeeding may be safely restarted following administration of sodium nitrite and sodium thiosulfate. In studies conducted with Long-Evans rats, sodium nitrite administered in drinking water during pregnancy and lactation resulted in severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, reduced growth and increased mortality in the offspring. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">There are case reports in the medical literature of sodium nitrite in conjunction with sodium thiosulfate being administered to pediatric patients with cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>; however, there have been no clinical studies to evaluate the safety or efficacy of sodium thiosulfate or sodium nitrite in the pediatric population. As for adult patients, dosing recommendations for pediatric patients have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports.</p>
<p>Sodium nitrite must be used with caution in patients less than 6 months of age because they may be at higher risk of developing severe <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> compared to older children and adults. The presence of fetal hemoglobin, which is oxidized to methemoglobin more easily than adult hemoglobin, and lower methemoglobin reductase levels compared to older children and adults may contribute to risk.</p>
<p>Mortality attributed to sodium nitrite was reported following administration of an adult dose (300 mg IV followed by a second dose of 150 mg) to a 17-month old child.<span class="Italics"> [see<a href="#S2"> Dosage and Administration (2)</a>,<a href="#S5"> Warnings and Precautions, (5)</a>,<a href="#S6"> Adverse Reactions (6)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Sodium nitrite and sodium thiosulfate are known to be substantially excreted by the kidney, and the risk of adverse reactions to these drugs may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> </h2>
<p class="First">Sodium nitrite and sodium thiosulfate are known to be substantially excreted by the kidney, and the risk of toxic reactions to these drugs may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10   OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Underline">Sodium Nitrite</span></p>
<p>Large doses of sodium nitrite result in severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and toxic levels of methemoglobin which may lead to <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.</p>
<p>Sodium nitrite administration has been reported to cause or significantly contribute to mortality in adults at oral doses as low as 1 g and intravenous doses as low as 600 mg. A <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> attributed to sodium nitrite has been reported following administration of an adult dose (300 mg IV followed by a second dose of 150 mg) to a 17-month old child.</p>
<p><span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">Cyanosis</span> may become apparent at a methemoglobin level of 10-20%. Other clinical signs and symptoms of sodium nitrite toxicity (<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) can be apparent at methemoglobin levels as low as 15%. More serious signs and symptoms, including <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">circulatory failure</span>, and central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> are seen as methemoglobin levels increase, and levels above 70% are usually fatal.</p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involves supplemental oxygen and supportive measures such as exchange transfusion. Treatment of severe <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> with intravenous methylene blue has been described in the medical literature; however, this may also cause release of cyanide bound to methemoglobin. Because <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> appears to be mediated primarily by an increase in venous capacitance, measures to increase venous return may be most appropriate to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Underline">Sodium Thiosulfate</span></p>
<p>There is limited information about the effects of large doses of sodium thiosulfate in humans. Oral administration of 3 g sodium thiosulfate per day for 1-2 weeks in humans resulted in reductions in room air arterial oxygen saturation to as low as 75%, which was due to a rightward shift in the oxygen hemoglobin dissociation curve. The subjects returned to baseline oxygen saturations 1 week after discontinuation of sodium thiosulfate. A single intravenous administration of 20 mL of 10% sodium thiosulfate reportedly did not change oxygen saturations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Sodium nitrite, one of the active ingredients in NITHIODOTE has the chemical name nitrous acid sodium salt. The chemical formula is NaNO<span class="Sub">2</span> and the molecular weight is 69.0. Sodium thiosulfate, the second active ingredient in NITHIODOTE has the chemical name thiosulfuric acid, disodium salt, pentahydrate. The chemical formula is Na<span class="Sub">2</span>S<span class="Sub">2</span>O<span class="Sub">3</span>• 5H<span class="Sub">2</span>O and the molecular weight is 248.17.  The structural formulae are:</p>
<p>Structure of Sodium Nitrite</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ff4941b3-9901-4aab-adcf-c5327bede34e&amp;name=nithiodote-01.jpg"></div>
<p>Structure of Sodium Thiosulfate Pentahydrate</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ff4941b3-9901-4aab-adcf-c5327bede34e&amp;name=nithiodote-02.jpg"></div>
<p>NITHIODOTE is a cyanide antidote which contains one 10 mL glass vial of a 3% solution of sodium nitrite injection and one 50 mL glass vial containing a 25% solution of sodium thiosulfate injection.</p>
<p>Sodium nitrite injection is a sterile aqueous solution and is intended for intravenous injection. Each vial contains 300 mg of sodium nitrite in 10 mL solution (30 mg/mL). Sodium nitrite injection is a clear solution with a pH between 7.0 and 9.0.</p>
<p>Sodium thiosulfate injection is a sterile aqueous solution and is intended for intravenous injection. Each vial contains 12.5 grams of sodium thiosulfate in 50 mL solution (250 mg/mL). Each mL also contains 2.8 mg boric acid and 4.4 mg of potassium chloride. The pH of the solution is adjusted with boric acid and/or sodium hydroxide. Sodium thiosulfate injection is a clear solution with a pH between 7.5 and 9.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Exposure to a high dose of cyanide can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. In massive acute cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, the mechanism of toxicity may involve other enzyme systems as well. </p>
<p>The synergy resulting from treatment of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with the combination of sodium nitrite and sodium thiosulfate is the result of differences in their primary mechanisms of action as antidotes for cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Underline">Sodium Nitrite</span></p>
<p>Sodium nitrite is thought to exert its therapeutic effect by reacting with hemoglobin to form methemoglobin, an oxidized form of hemoglobin incapable of oxygen transport but with high affinity for cyanide. Cyanide preferentially binds to methemoglobin over cytochrome a<span class="Sub">3</span>, forming the nontoxic cyanomethemoglobin. Methemoglobin displaces cyanide from cytochrome oxidase, allowing resumption of aerobic metabolism. The chemical reaction is as follows: </p>
<p>NaNO<span class="Sub">2</span> + Hemoglobin → Methemoglobin<br>HCN + Methemoglobin → Cyanomethemoglobin</p>
<p>Vasodilation has also been cited to account for at least part of the therapeutic effect of sodium nitrite. It has been suggested that sodium nitrite-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> may be more efficacious against cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> than comparable levels of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> induced by other oxidants. Also, sodium nitrite appears to retain some efficacy even when the formation of methemoglobin is inhibited by methylene blue. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Underline">Sodium Thiosulfate</span></p>
<p>The primary route of endogenous cyanide detoxification is by enzymatic transulfuration to thiocyanate (SCN<span class="Sup">-</span>), which is relatively nontoxic and readily excreted in the urine. Sodium thiosulfate is thought to serve as a sulfur donor in the reaction catalyzed by the enzyme rhodanese, thus enhancing the endogenous detoxification of cyanide in the following chemical reaction:</p>
<table width="50%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center">Rhodanese</td></tr>
<tr class="Botrule Last"><td align="center">Na<span class="Sub">2</span>S<span class="Sub">2</span>O<span class="Sub">3</span> + CN<span class="Sup">-</span>    →         SCN<span class="Sup">-</span> + Na<span class="Sub">2</span>SO<span class="Sub">3</span>.</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12. 2        Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Sodium Nitrite</span></p>
<p>When 4 mg/kg sodium nitrite was administered intravenously to six healthy human volunteers, the mean peak methemoglobin concentration was 7%, achieved at 30-60 minutes after injection, consistent with reports in cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> victims. Supine systolic and diastolic blood pressures dropped approximately 20% within 10 minutes, a drop which was sustained throughout the 40 minutes of testing. This was associated with a 20 beat per minute increase in pulse rate that returned to baseline in 10 minutes. Five of these subjects were unable to withstand orthostatic testing due to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. One additional subject, who received a 12 mg/kg dose of sodium nitrite, experienced severe cardiovascular effects and achieved a peak methemoglobin concentration of 30% at 60 minutes following injection. </p>
<p>Oral doses of 120 to 180 mg of sodium nitrite administered to healthy volunteers caused minimal cardiovascular changes when subjects were maintained in the horizontal position. However, minutes after being placed in the upright position subjects exhibited <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. </p>
<p>The half life for conversion of methemoglobin to normal hemoglobin in a cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> victim who has been administered sodium nitrite and sodium thiosulfate is estimated to be 55 minutes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Sodium Thiosulfate</span></p>
<p>In dogs, pretreatment with sodium thiosulfate to achieve a steady state level of 2 µmol/mL increased the rate of conversion of cyanide to thiocyanate over 30-fold.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Sodium Nitrite</span></p>
<p>Sodium nitrite is a strong oxidant, and reacts rapidly with hemoglobin to form methemoglobin. The pharmacokinetics of free sodium nitrite in humans have not been well studied. It has been reported that approximately 40% of sodium nitrite is excreted unchanged in the urine while the remaining 60% is metabolized to <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> and related small molecules. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Sodium Thiosulfate</span></p>
<p>Thiosulfate taken orally is not systemically absorbed. Most of the thiosulfate is oxidized to sulfate or is incorporated into endogenous sulphur compounds; a small proportion is excreted through the kidneys. Approximately 20-50% of exogenously administered thiosulfate is eliminated unchanged via the kidneys. After an intravenous injection of 1 g sodium thiosulfate in patients, the reported serum thiosulfate half-life was approximately 20 minutes. However, after an intravenous injection of a substantially higher dose of sodium thiosulfate (150 mg/kg, that is, 9 g for 60 kg body weight) in normal healthy men, the reported elimination half-life was 182 minutes.   </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Underline">Cyanide</span></p>
<p>The apparent terminal elimination half life and volume of distribution of cyanide, in a patient treated for an acute cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> with sodium nitrite and sodium thiosulfate administration, have been reported to be 19 hours and 0.41 L/kg, respectively. Additionally, an initial elimination half life of cyanide has been reported to be approximately 1-3 hours. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Thiocyanate</span></p>
<p>After detoxification, in healthy subjects, thiocyanate is excreted mainly in the urine at a rate inversely proportional to creatinine clearance. In healthy subjects, the elimination half-life and volume of distribution of thiocyanate have been reported to be 2.7 days and 0.25 L/kg, respectively. However, in subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> the reported elimination half life is approximately 9 days.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The potential benefit of an acute exposure to sodium nitrite as part of a cyanide antidote outweighs concerns raised by the equivocal findings in chronic rodent studies. Sodium nitrite (0, 750, 1500, or 3000 ppm equivalent to average daily doses of approximately 0, 35, 70, or 130 mg/kg for males and 0, 40, 80, or 150 mg/kg for females) was orally  administered to rats (Fischer 344 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>) for 2 years via drinking water. There were no significant increases in the incidence of tumor in either male or female rats. Sodium nitrite (0, 750, 1500, or 3000 ppm equivalent to average daily doses of approximately 0, 60, 120, or 220 mg/kg for males and 0, 45, 90, or 165 mg/kg for females) was administered to B6C3F1 mice for 2 years via the drinking water. Equivocal results were obtained in female mice. Specifically, there was a positive trend toward an increase in the incidence of squamous cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> or carcinoma in the forestomach of female mice. Although the incidence of <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> of the glandular stomach epithelium was significantly greater in the high-dose male mice compared to controls, there were no significant increases in tumors in the male mice. Numerous reports in the published literature indicate that sodium nitrite may react<span class="Italics"> in vivo </span>with secondary amines to form carcinogenic nitrosamines in the stomach. Concurrent exposure to sodium nitrite and secondary amines in feed or drinking water resulted in an increase in the incidence of tumors in rodents. </p>
<p>Long-term studies in animals have not been performed to evaluate the potential carcinogenicity of sodium thiosulfate.</p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis:</span></p>
<p>Sodium nitrite is mutagenic in<span class="Italics"> S. typhimurium </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA100, TA1530, TA1535 with and without metabolic activation; however, it was negative in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA98, TA102, DJ460 and<span class="Italics"> E. coli </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WP2UVRA/PKM101. Sodium nitrite has been reported to be genotoxic to V79 hamster cells<span class="Italics"> in vitro </span>and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, both assays conducted in the absence of metabolic activation. Sodium nitrite was negative in the in vitro chromosomal aberrations assay using human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Acute administration of sodium nitrite to male rats or male mice did not produce an increased incidence of micronuclei in bone marrow. Likewise, sodium nitrite administration to mice for 14-weeks did not result in an increase in the incidence of micronuclei in the peripheral blood. </p>
<p>The mutagenic potential of sodium thiosulfate has been examined in the<span class="Italics"> in vitro </span>Bacterial Reverse Mutation Assay (Ames Assay). Sodium thiosulfate was not mutagenic in the absence of metabolic activation in<span class="Italics"> S. typhimurium </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA98, TA100, TA1535, TA537, or TA1538. Sodium thiosulfate was not mutagenic in the presence of metabolic activation in <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA1535, TA1537, TA1538 or<span class="Italics"> E. coli </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WP2.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Underline">Fertility</span>:</p>
<p>Clinical studies to evaluate the potential effects of either sodium nitrite or sodium thiosulfate intake on fertility of either males or females have not been reported. In contrast, multigenerational fertility and reproduction studies conducted by the National Toxicology Program did not detect any evidence of an effect of sodium nitrite (0.0, 0.06, 0.12, and 0.24% weight/volume) on either fertility or any reproductive parameter in Swiss CD-1 mice. This treatment protocol resulted in approximate doses of 125, 260, and 425 mg/kg/day. The highest exposure in this mouse study is 4.6 times greater than the highest clinical dose of sodium nitrite that would be used to treat cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> (based on a body surface area comparison).</p>
<p>There are no preclinical studies examining the effects of sodium thiosulfate on fertility.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2	Animal Pharmacology</h2>
<p class="First">Due to the extreme toxicity of cyanide, experimental evaluation of treatment efficacy has predominantly been completed in animal models. The efficacy of sodium thiosulfate treatment alone to counteract the toxicity of cyanide was initially reported in 1895 by Lang. The efficacy of amyl nitrite treatment in cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> of the dog model was first reported in 1888 by Pedigo. Further studies in the dog model, which demonstrated the utility of sodium nitrite as a therapeutic intervention, were reported in 1929 by Mladoveanu and Gheorghiu. However, Hugs and Chen et al. independently reported upon the superior efficacy of the combination of sodium nitrite and sodium thiosulfate in 1932-1933. Treatment consisted of intravenously administered 22.5 mg/kg (half the lethal dose) sodium nitrite or 1 g/kg sodium thiosulfate alone or in sequence immediately after subcutaneous injection of sodium cyanide into dogs over a range of doses. Subsequent doses of 10 mg/kg sodium nitrite and/or 0.5 g/kg sodium thiosulfate were administered when clinical signs or symptoms of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> persisted or reappeared. Either therapy administered alone increased the dose of sodium cyanide required to cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and when administered together, sodium nitrite and sodium thiosulfate resulted in a synergistic effect in raising the lethal dose of sodium cyanide. The combined therapy appeared to have reduced efficacy when therapy was delayed until signs of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> (e.g. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>) appeared; however, other investigators have reported survival in dogs that were administered antidotal treatment after <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> had occurred. </p>
<p>Animal studies conducted in other species (e.g., rat, guinea pig, sheep, pigeon and cat) have also supported a synergistic effect of intravenous sodium nitrite and sodium thiosulfate in the treatment of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.</p>
<p>While intravenous injection of sodium nitrite and sodium thiosulfate was effective in reversing the effects of lethal doses of cyanide in dogs, intramuscular injection of sodium nitrite, with or without sodium thiosulfate, was found not to be effective in the same setting.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The human data supporting the use of sodium nitrite for cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> consists primarily of published case reports. There are no randomized controlled clinical trials. Nearly all the human data describing the use of sodium thiosulfate report its use in conjunction with sodium nitrite. Dosing recommendations for humans have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports.</p>
<p>There have been no human studies to prospectively and systematically evaluate the safety of sodium thiosulfate or sodium nitrite in humans. Available human safety information is based largely on anecdotal case reports and case series of limited scope.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each NITHIDOTE carton (NDC 60267-812-00) consists of the following:</p>
<ul class="Disc">
<li>One 10 mL glass vial of sodium nitrite injection 30 mg/mL (containing 300 mg of sodium nitrite);</li>
<li>One 50 mL glass vial of sodium thiosulfate injection 250 mg/mL (containing 12.5 grams of sodium thiosulfate);</li>
<li>One package insert.</li>
</ul>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at controlled room temperature between 20°C and 25°C (68°F - 77°F); excursions permitted to 15-30°C (59 to 86°F).</p>
<p>Protect from direct light. Do not freeze.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">NITHIODOTE is indicated for cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and in this setting, patients will likely be unresponsive or may have difficulty in comprehending counseling information.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and Methemoglobin Formation </h2>
<p class="First">When feasible, patients should be informed of the possibility of life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and methemoglobin formation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Monitoring</h2>
<p class="First">Where feasible, patients should be informed of the need for close monitoring of blood pressure and oxygenation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured by Cangene BioPharma, Inc., Baltimore, Maryland  21230 for<br>Hope Pharmaceuticals, Scottsdale, Arizona  85260 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Kit Carton</span></p>
<p><span class="Bold">NDC 60267-812-00<br>Rx Only</span></p>
<p><span class="Bold">NITHIODOTE™<br>Sodium Nitrite Injection, USP<br>and<br>Sodium Thiosulfate Injection, USP</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE<br>SINGLE USE ONLY</span></p>
<p>Any unused portion of a vial should be discarded.</p>
<p>Box Contains:</p>
<p>Sodium Nitrite Injection, USP<br><span class="Bold">300 mg/10 mL</span><br>(30 mg/mL)</p>
<p>and</p>
<p>Sodium Thiosulfate Injection, USP<br><span class="Bold">12.5 grams/50 mL</span><br>(250 mg/mL)</p>
<p>Manufactured by<br>CANGENE bioPharma, Inc.<br>Baltimore, MD for</p>
<p><span class="Bold">HOPE<br>PHARMACUETICALS ®</span><br>Scottsdale, AZ 85260 U.S.A.</p>
<div class="Figure"><img alt="Principal Display Panel - Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ff4941b3-9901-4aab-adcf-c5327bede34e&amp;name=nithiodote-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NITHIODOTE 		
					</strong><br><span class="contentTableReg">sodium nitrite and sodium thiosulfate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60267-812</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60267-812-00</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">10 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">50 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SODIUM NITRITE 		
					</strong><br><span class="contentTableReg">sodium nitrite injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60267-311</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sodium Nitrite</strong> (Sodium Cation) </td>
<td class="formItem">Sodium Nitrite</td>
<td class="formItem">30 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60267-311-10</td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201444</td>
<td class="formItem">01/14/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>SODIUM THIOSULFATE 		
					</strong><br><span class="contentTableReg">sodium thiosulfate injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60267-705</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Sodium Thiosulfate</strong> (Sodium Cation) </td>
<td class="formItem">Sodium Thiosulfate</td>
<td class="formItem">250 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Potassium Chloride</strong></td>
<td class="formItem">4.4 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Boric Acid</strong></td>
<td class="formItem">2.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Boric Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60267-705-50</td>
<td class="formItem">50 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201444</td>
<td class="formItem">01/14/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201444</td>
<td class="formItem">01/14/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hope Pharmaceuticals
							(015227945)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cangene Biopharma, Inc.</td>
<td class="formItem"></td>
<td class="formItem">050783398</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d8dff852-99cb-47e2-9c48-b7c81e90ec6e</div>
<div>Set id: ff4941b3-9901-4aab-adcf-c5327bede34e</div>
<div>Version: 1</div>
<div>Effective Time: 20110126</div>
</div>
</div> <div class="DistributorName">Hope Pharmaceuticals</div></p>
</body></html>
